SERPINA12 antibody
- Known as:
- SERPINA12 (anti-)
- Catalog number:
- orb101158
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- SERPINA12 antibody
Related genes to: SERPINA12 antibody
- Gene:
- SERPINA12 NIH gene
- Name:
- serpin family A member 12
- Previous symbol:
- -
- Synonyms:
- OL-64, Vaspin
- Chromosome:
- 14q32.13
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-21
- Date modifiied:
- 2016-04-06
Related products to: SERPINA12 antibody
Related articles to: SERPINA12 antibody
- - Source: PubMed
Publication date: 2026/06/14
Pan LuluBu Zhangyu - SERPINA12 is a member of the serpin superfamily that has been extensively studied in metabolic and inflammatory disorders. In recent years, increasing evidence has highlighted its emerging role in skin physiology and dermatological diseases. SERPINA12 is expressed in multiple skin cell types, including keratinocytes and dermal fibroblasts, where it participates in the regulation of inflammation, cellular proliferation, differentiation, and tissue homeostasis. Dysregulation of SERPINA12 has been implicated in several skin disorders. In psoriasis, altered SERPINA12 expression is associated with chronic inflammation, immune dysregulation, and abnormal keratinocyte proliferation, suggesting a potential modulatory role in psoriatic pathogenesis. Furthermore, emerging studies suggest a possible involvement of SERPINA12 in palmoplantar keratoderma, where it may contribute to aberrant keratinization and epidermal barrier dysfunction. This review summarizes current knowledge on the expression patterns, biological functions, and molecular mechanisms of SERPINA12 in the skin, with a particular focus on adipocytes, psoriasis, and palmoplantar keratoderma. Understanding the role of SERPINA12 in cutaneous biology may provide new insights into disease pathogenesis and identify potential therapeutic targets for skin disorders. - Source: PubMed
Publication date: 2026/04/27
Xiao ZhenzhenWang FeiLi RuiTan Yingjian - Cardiometabolic diseases are chronic conditions arising from the common pathophysiology of metabolic and cardiovascular disorders accompanied by risk factors such as insulin resistance, obesity, type 2 diabetes, metabolic syndrome, and hypertension. In recent years, the relationship between adipokines such as PAI-1 and vaspin and these diseases has attracted increasing interest. PAI-1 increases cardiovascular risks by inhibiting fibrinolysis, and high PAI-1 levels are associated with obesity and insulin resistance. Vaspin, on the other hand, may have an inhibitory effect on the development of type 2 diabetes and metabolic syndrome by increasing insulin sensitivity. Considering the effects of dietary and lifestyle factors on these molecules, PAI-1 and vaspin are thought to have potential as early biomarkers and therapeutic targets. However, conflicting findings in the literature necessitate further research. Alongside lifestyle interventions based on healthy eating and exercise, changes in PAI-1 and vaspin levels show promise as potential biomarkers for the early diagnosis and prevention of cardiometabolic disorders and the development of personalized treatment strategies. Further research is required to better clarify the molecular mechanisms regulating PAI-1 and vaspin and to determine their potential clinical applications in the prevention and management of cardiometabolic diseases. - Source: PubMed
Publication date: 2026/03/26
Kocabas SuleSanlier Nevin - - Source: PubMed
Publication date: 2026/04/05
Pan LuluBu Zhangyu - The American Heart Association's Life's Essential 8 cardiovascular health (CVH) construct strongly predicts cardiovascular disease (CVD), yet biological processes associated with early-life CVH trajectories are unclear. We examined associations of CVH score and trajectory parameters across childhood with cardiovascular-related proteins. - Source: PubMed
Publication date: 2026/04/03
Lin ZhiRifas-Shiman Sheryl Lde Ferranti Sarah DPerng WeiHivert Marie-FranceAris Izzuddin M